The emergency use authorization (EUA) of 2 mRNA-based vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) heralded a rapid nationwide rollout to slow down the surge of coronavirus disease 2019 (COVID-19) infections. These vaccines have been highly effective in phase 3 clinical trials, offering recipients 94% to 95% protection from infection.
1,2 However, stringent exclusion criteria excluded many individuals with chronic liver disease. For example, the phase 3 trial of the Pfizer BNT162b2 mRNA vaccine against COVID-19 excluded individuals with an anticipated need for immunosuppression, and those with active hepatitis B or C infection.
1 Only 217 (0.6%) of participants had liver disease, with just 3 (<0.01%) with moderate-to-severe liver disease.
3 A similarly low proportion of patients with liver disease were included in the Moderna mRNA-1273 trial with only 196 (0.6%) with liver disease.
2,3